Specialty Pharma Journal Specialty, Precision & Technology
Cambridge, UK, 14 February 2017: Horizon Discovery Group plc (LSE: HZD) (“Horizon” or the “Group”), the world leader in the application of gene editing technologies, today announces the signing of a Master Services Agreement (MSA) with a top three global pharmaceutical company (the “Company”), extending support for their drug discovery …
Tag Archives: gene editing technology
February, 2017
May, 2016
-
17 May
Bayer and ERS Genomics Announce Licensing Agreement for Genome-Editing Patents
LEVERKUSEN, Germany & DUBLIN–(BUSINESS WIRE)–Bayer and ERS signed a patent license agreement whereby Bayer gains access to ERS’ CRISPR-Cas9 genome-editing patents for certain cross-divisional applications in Bayer’s core strategic areas. ERS Genomics holds rights to the foundational CRISPR-Cas9 patent portfolio from Dr. Emmanuelle Charpentier, an inventor of the breakthrough gene-editing …
December, 2015
-
21 December
Bayer Partners with CRISPR Therapeutics to Develop New Gene Therapies
LEVERKUSEN, Germany and BASEL, Switzerland, Dec. 21, 2015 /PRNewswire/ — Bayer and CRISPR Therapeutics have entered into an agreement to create a joint venture (JV) to discover, develop and commercialize new breakthrough therapeutics to cure blood disorders, blindness, and congenital heart disease. CRISPR Therapeutics will contribute its proprietary CRISPR-Cas9 gene-editing technology …